Brief: Cipla Says USFDA Classified Verna Manufacturing Facility Inspection As Voluntary Action Indicated
11/06/2026 09:27
BRIEF-Cipla Says USFDA Classified Verna Manufacturing Facility Inspection As Voluntary Action Indicated June 11 (Reuters) - Cipla Ltd CIPL.NS:
USFDA CLASSIFIED VERNA MANUFACTURING FACILITY INSPECTION AS VOLUNTARY ACTION INDICATED
Source text: ID:nnAZN4T1SB5
Further company coverage: CIPL.NS
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Cipla
See all newsIndian pharma stocks up on report US taps drugmakers for critical cancer drug
India's Cipla jumps after Citi sees near-term positive triggers for earnings
Factbox: Global drugmakers invest billions to boost US presence
India raises price cap on cancer drugs to tackle shortage
Brief: Cipla Says USFDA Classified Verna Manufacturing Facility Inspection As Voluntary Action Indicated